Patents by Inventor Nobutaka Hattori

Nobutaka Hattori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210147400
    Abstract: Provided is a novel process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative. More specifically, provided is a process for producing a (2S)-2-[(1H-pyrazol-1-yl)methyl]-1,3-oxazinane derivative represented by formula (1): the process comprising reacting 3-aminopropan-1-ol with glyoxylic acid.
    Type: Application
    Filed: July 11, 2018
    Publication date: May 20, 2021
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Takaaki MATSUBARA, Hiroki URABE, Ryo SUZUKI, Aya FUTAMURA, Ryo KINOSHITA, Nobutaka HATTORI, Hideaki TABUSE, Koreaki IMURA, Norikazu OTAKE
  • Patent number: 9522914
    Abstract: The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: December 20, 2016
    Assignee: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Mitsukane Yoshinaga, Takeshi Kuwada, Naoki Miyakoshi, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki
  • Publication number: 20160159814
    Abstract: The present invention provides novel compounds of formula [I] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.
    Type: Application
    Filed: July 25, 2014
    Publication date: June 9, 2016
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Daisuki WAKASUGI, Hiroshi OHTA, Kumiko OKADA, Shin-ichi SHIROKAWA, Minoru MORIYA, Tomoko TAMITA, Kumi ABE, Nobutaka HATTORI, Yuko ARAKI
  • Patent number: 9193695
    Abstract: The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: November 24, 2015
    Assignee: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Kuwada, Mitsukane Yoshinaga, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki, Naoki Miyakoshi
  • Publication number: 20150045551
    Abstract: The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia.
    Type: Application
    Filed: March 29, 2013
    Publication date: February 12, 2015
    Applicant: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Mitsukane Yoshinaga, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Shuhei Kashiwa, Takeshi Kuwada, Youichi Shimazaki
  • Publication number: 20140275006
    Abstract: The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth.
    Type: Application
    Filed: October 25, 2012
    Publication date: September 18, 2014
    Applicant: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Mitsukane Yoshinaga, Takeshi Kuwada, Naoki Miyakoshi, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki
  • Publication number: 20140081025
    Abstract: The compound represented by formula (IA) or a pharmaceutically acceptable salt thereof is based on orexin (OX) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.
    Type: Application
    Filed: May 8, 2012
    Publication date: March 20, 2014
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Ryo Suzuki, Aya Futamura, Masahito Abe, Shuhei Kashiwa, Nobutaka Hattori, Dai Nozawa, Hiroshi Ohta, Yuko Araki
  • Publication number: 20130197217
    Abstract: The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.
    Type: Application
    Filed: September 30, 2011
    Publication date: August 1, 2013
    Applicant: TAISHO PHARMACEUTICAL CO., LTD
    Inventors: Takeshi Kuwada, Mitsukane Yoshinaga, Tomoko Ishizaka, Daisuke Wakasugi, Shin-ichi Shirokawa, Nobutaka Hattori, Youichi Shimazaki, Naoki Miyakoshi
  • Publication number: 20060051835
    Abstract: An object of the present invention is to provide a substrate of Parkin, a system for elucidating the cause of Parkinson's disease using the substrate and a method of screening for a remedy for Parkinson's disease. An animal cell having a DNA encoding a human Pael receptor or a DNA having a variant of the DNA incorporated therein; a non-human mammal having a DNA carrying the aforementioned DNA incorporated therein; a probe comprising the whole or a part of DNA encoding the human Pael receptor; and an antibody specifically recognizing Pael receptor.
    Type: Application
    Filed: June 28, 2002
    Publication date: March 9, 2006
    Inventors: Ryosuke Takahashi, Yuzuru Imai, Nobutaka Hattori, Yoshikuni Mizuno, Mariko Soda, Haruhisa Inoue
  • Patent number: 4533705
    Abstract: A process for producing .alpha.-olefin polymers having high crystallinity and good particle form, with a high yield is provided. The polymerization therefor is carried out in the presence of a preactivated catalyst suitable particularly to gas phase polymerization or gas phase polymerization following slurry or bulk polymerization.The catalyst is prepared by reacting a reduction solid prepared by reducing TiCl.sub.4 with an organoaluminum compound, with an electron donor and an electron acceptor to obtain a solid product, andcombining this solid product with an organoaluminum compound, an .alpha.-olefin and a reaction product of an organoaluminum compound with an electron donor.
    Type: Grant
    Filed: July 21, 1983
    Date of Patent: August 6, 1985
    Assignee: Chisso Corporation
    Inventors: Akihiro Sato, Kazutsune Kikuta, Toshihiro Uwai, Kenji Matsuda, Nobutaka Hattori